MYRIAD GENETICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Index to Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 77 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 79 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025, 2024 and 2023 | 80 |
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2025, 2024 and 2023 | 81 |
| Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2025, 2024 and 2023 | 82 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024 and 2023 | 83 |
| Notes to Consolidated Financial Statements | 84 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.